TITLE:
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

CONDITION:
Diarrhea

INTERVENTION:
Octreotide

SUMMARY:

      The primary objective of this study is to determine the relapse rate in patients with
      AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled,
      double-blind study of Sandostatin (Study #D203 - FDA 102A).

      The secondary objectives include: 1) To evaluate clinical efficacy and safety of open-label
      Sandostatin in patients who were "Non-Responders" in Study #D203 - FDA 102A; 2) To evaluate
      the efficacy and safety of Sandostatin during prolonged open-label treatment in "Responders"
      from Study #D03 - FDA 102A.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have the following:

          -  Only patients who have completed the duration of Study D203, FDA 102A will be
             eligible for this study.

          -  Each of these patients must give written informed consent to participate in Study
             D204, FDA 102B as well.
      
